Lavipharm Group
http://www.lavipharm.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Lavipharm Group
Asia Deal Watch: Biocytogen Antibody Candidates To Be Evaluated By ADC Therapeutics
Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.
Greece prices will fall again with harsh reimbursement list criteria
The Greek government is pushing forth with negative and positive drug lists as a way to cut public pharmaceutical expenditure from about €4.3 billion for 2010 to €3.4 billion in 2011. Public pharma expenditure has fallen already significantly from the €5.1 billion in 2009, where €850 million worth of savings were made in 2010, of which €500 million were the result of drug price cuts.
US FDA orders classwide REMS for long-acting opioids
The US FDAis requiring 16 manufacturers of 24 branded and generic opioid medicines to jointly develop a classwide risk evaluation and mitigation strategy (REMS) to reduce deaths and serious injuries resulting from misuse, abuse and overdose.
Teva launches transdermal fentanyl in the US
Teva Pharmaceutical Industrieshas received US FDA approval and started shipping its fentanyl transdermal patches, in 25, 50, 75 and 100 μg/hour doses, AB-rated generic versions of Ortho-McNeil's (J&J) Duragesic. Generic fentanyl patches are already available in the US from other companies, including Mylan, Watson, Lavipharm and Actavis. Earlier this year, lots of Watson's and Actavis's versions were separately adversely affected by manufacturing issues. Teva's version is manufactured by Aveva Drug Delivery Systems, a division of Nitto Denko, which Teva describes as one of the world's largest manufacturers of, and pioneer in, drug-in-adhesive transdermal patch technology.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice